Posology : מינונים

4.2       Posology and method of administration

Zoledronic Acid Taro must only be prescribed and administered to patients by healthcare professionals experienced in the administration of intravenous bisphosphonates. Patients treated with Zoledronic Acid Taro should be given the package leaflet.

Posology
Multiple Myeloma and bone metastases from solid tumors
Adults and older people
The recommended dose is 4 mg zoledronic acid every 3 to 4 weeks.

Patients should also be administered an oral calcium supplement of 500 mg and 400 IU vitamin D daily.
The decision to treat patients with bone metastases for the prevention of skeletal related events should consider that the onset of treatment effect is 2-3 months.

Treatment of hypercalcemia of malignancy (HCM)
Adults and older people
The recommended dose in hypercalcaemia (albumin-corrected serum calcium  12.0 mg/dl or 3.0 mmol/l) is a single dose of 4 mg zoledronic acid.
Patients must be maintained well hydrated prior to and following administration of Zoledronic Acid Taro.

Renal impairment
Patients with hypercalcemia of malignancy (HCM):
Zoledronic Acid Taro treatment in patients with hypercalcemia of malignancy (HCM) who also have severe renal impairment should be considered only after evaluating the risks and benefits of treatment. In the clinical studies, patients with serum creatinine > 400 μmol/l or > 4.5 mg/dl were excluded. No dose adjustment is necessary in HCM patients with serum creatinine < 400 μmol/l or < 4.5 mg/dl (see section 4.4).

Multiple Myeloma and bone metastases from solid tumors:
When initiating treatment with Zoledronic Acid Taro in adult patients with multiple myeloma or metastatic bone lesions from solid tumours, serum creatinine and creatinine clearance (CLcr) should be determined. CLcr is calculated from serum creatinine using the Cockcroft-Gault formula. Zoledronic Acid Taro is not recommended for patients presenting with severe renal impairment prior to initiation of therapy, which is defined for this population as CLcr < 30 ml/min. In clinical trials with Zoledronic Acid Taro, patients with serum creatinine > 265 μmol/l or > 3.0 mg/dl were excluded.

In patients with bone metastases presenting with mild to moderate renal impairment prior to initiationof therapy, which is defined for this population as CLcr 30–60 ml/min, the following Zoledronic Acid Taro dose is recommended (see also section 4.4):

Baseline creatinine clearance (ml/min)                      Zoledronic Acid Taro recommended dose*
> 60                                     4.0 mg zoledronic acid
50–60                                    3.5 mg* zoledronic acid
40–49                                    3.3 mg* zoledronic acid
30–39                                    3.0 mg* zoledronic acid
* Doses have been calculated assuming target AUC of 0.66 (mg•hr/l) (CLcr = 75 ml/min). The reduced doses for patients with renal impairment are expected to achieve the same AUC as that seen in patients with creatinine clearance of 75 ml/min.

Following initiation of therapy, serum creatinine should be measured prior to each dose of Zoledronic Acid Taro and treatment should be withheld if renal function has deteriorated. In the clinical trials, renal deterioration was defined as follows:
-   For patients with normal baseline serum creatinine (< 1.4 mg/dl or < 124 µmol/l), an increase of 0.5 mg/dl or 44 µmol/l;
-   For patients with abnormal baseline creatinine (> 1.4 mg/dl or > 124 µmol/l), an increase of 1.0 mg/dl or 88 µmol/l.

In the clinical studies, zoledronic acid treatment was resumed only when the creatinine level returned to within 10% of the baseline value (see section 4.4). Zoledronic Acid Taro treatment should be resumed at the same dose as that given prior to treatment interruption.

Paediatric population
The safety and efficacy of zoledronic acid in children aged 1 year to 17 years have not been established.
Currently available data are described in section 5.1 but no recommendation on a posology can be made.

Method of administration
Intravenous use.
Zoledronic Acid Taro 4 mg concentrate for solution for infusion, further diluted in 100 ml (see section 6.6), should be given as a single intravenous infusion in no less than 15 minutes.

In patients with mild to moderate renal impairment, reduced Zoledronic Acid Taro doses are recommended (see section “Posology” above and section 4.4).

Instructions for preparing reduced doses of Zoledronic Acid Taro

Withdraw an appropriate volume of the concentrate needed, as follows: -    4.4 ml for 3.5 mg dose
-    4.1 ml for 3.3 mg dose
-    3.8 ml for 3.0 mg dose

For instructions on the dilution of the medicinal product before administration, see section 6.6. The withdrawn amount of concentrate must be further diluted in 100 ml of sterile 0.9% w/v sodium chloride solution or 5% w/v glucose solution. The dose must be given as a single intravenous infusion over no less than 15 minutes.

Zoledronic Acid Taro concentrate must not be mixed with calcium or other divalent cation-containing infusion solutions such as lactated Ringer’s solution, and should be administered as a single intravenous solution in a separate infusion line.

Patients must be maintained well hydrated prior to and following administration of Zoledronic Acid Taro.